advancing human health requires a greater understanding of biology, and that understanding starts with the cell. we enable researchers to drive exponential progress in oncology, immunology, neuroscience, and more with novel single cell, spatial, and in situ tools that have been cited in over 3,000 publications and continually improved by our dedicated scientific team. our aim: to develop innovative instruments, reagents, and software that allow you to see your biological system at a resolution that matches its complexity.
Company profile
Ticker
TXG
Exchange
Website
CEO
Serge Saxonov
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
10X Genomics, Inc.
SEC CIK
Corporate docs
IRS number
455614458
TXG stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
12 Apr 24
S-8
Registration of securities for employees
15 Feb 24
10-K
2023 FY
Annual report
15 Feb 24
8-K
10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024
15 Feb 24
8-K
Departure of Directors or Certain Officers
16 Jan 24
8-K
10x Genomics Announces Preliminary Fourth Quarter and Full Year 2023 Results
8 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
10x Genomics Reports Third Quarter 2023 Financial Results
2 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
10x Genomics Reports Second Quarter 2023 Financial Results
3 Aug 23
Transcripts
TXG
Earnings call transcript
2023 Q4
15 Feb 24
TXG
Earnings call transcript
2023 Q3
2 Nov 23
TXG
Earnings call transcript
2023 Q2
3 Aug 23
TXG
Earnings call transcript
2023 Q1
3 May 23
TXG
Earnings call transcript
2022 Q4
15 Feb 23
TXG
Earnings call transcript
2022 Q3
3 Nov 22
TXG
Earnings call transcript
2022 Q2
9 Aug 22
TXG
Earnings call transcript
2022 Q1
5 May 22
TXG
Earnings call transcript
2021 Q4
17 Feb 22
TXG
Earnings call transcript
2022 Q2
4 Nov 21
Latest ownership filings
4
Serge Saxonov
25 Mar 24
4
Benjamin J. Hindson
25 Mar 24
4
Justin J. McAnear
25 Mar 24
4
Serge Saxonov
18 Mar 24
4
Serge Saxonov
6 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
4
Serge Saxonov
26 Feb 24
4
Benjamin J. Hindson
26 Feb 24
4
Justin J. McAnear
26 Feb 24
144
Notice of proposed sale of securities
22 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 314.74 mm | 314.74 mm | 314.74 mm | 314.74 mm | 314.74 mm | 314.74 mm |
Cash burn (monthly) | 5.37 mm | (no burn) | 31.60 mm | 19.44 mm | 8.43 mm | 2.27 mm |
Cash used (since last report) | 36.56 mm | n/a | 215.03 mm | 132.27 mm | 57.40 mm | 15.44 mm |
Cash remaining | 278.18 mm | n/a | 99.70 mm | 182.47 mm | 257.34 mm | 299.29 mm |
Runway (months of cash) | 51.8 | n/a | 3.2 | 9.4 | 30.5 | 131.9 |
Institutional ownership, Q3 2023
95.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 253 |
Opened positions | 33 |
Closed positions | 48 |
Increased positions | 77 |
Reduced positions | 96 |
13F shares | Current |
---|---|
Total value | 3.66 tn |
Total shares | 100.91 mm |
Total puts | 180.00 k |
Total calls | 372.80 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
FMR | 12.67 mm | $522.51 bn |
Vanguard | 8.90 mm | $367.27 bn |
Baillie Gifford & Co | 8.34 mm | $344.06 bn |
BLK Blackrock | 5.49 mm | $226.31 bn |
Venrock Associates VI | 4.83 mm | $0.00 |
MS Morgan Stanley | 4.35 mm | $179.44 bn |
Sands Capital Management | 3.99 mm | $164.40 bn |
Brown Capital Management | 3.08 mm | $127.10 bn |
ARK Investment Management | 2.99 mm | $123.48 bn |
T. Rowe Price | 2.69 mm | $111.18 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Mar 24 | Saxonov Serge | Class A Common Stock | Grant | Acquire A | No | No | 0 | 88,854 | 0.00 | 894,518 |
21 Mar 24 | Hindson Benjamin J. | Class A Common Stock | Grant | Acquire A | No | No | 0 | 71,083 | 0.00 | 354,142 |
21 Mar 24 | Justin J. McAnear | Class A Common Stock | Grant | Acquire A | No | No | 0 | 53,312 | 0.00 | 148,552 |
14 Mar 24 | Saxonov Serge | Class A Common Stock | Gift | Dispose G | No | No | 0 | 1,086 | 0.00 | 805,664 |
22 Feb 24 | Saxonov Serge | Class A Common Stock | Sell | Dispose S | No | No | 46.3443 | 2,821 | 130.74 k | 847,560 |
News
Geopolitical Relief Triggers Gold Selloff: Prices Dip Below $2,350 Mark, Mining Stocks Hit Hard
22 Apr 24
The Analyst Landscape: 4 Takes On 10x Genomics
18 Apr 24
Deutsche Bank Maintains Buy on 10x Genomics, Lowers Price Target to $55
18 Apr 24
Barclays Maintains Overweight on 10x Genomics, Lowers Price Target to $45
10 Apr 24
Cathie Wood's Ark Invest Sheds $6.4M Worth Of Coinbase Shares Despite Positive Market Movements, Analyst Upgrade
4 Apr 24
Press releases
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
10 Apr 24
10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
21 Mar 24
Johnson Fistel Announces Investigation of 10x Genomics (TXG) for Potential Securities Law Violations
14 Mar 24
10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting
5 Feb 24
TXG Alert: Johnson Fistel Announces Investigation of 10x Genomics for Potential Securities Law Violations
1 Feb 24